CLAIMS

1. An inhibitor of IL-6 production comprising, a hydroxamic acid derivative of the formula (I):



(I)

wherein, R^1 is
(a) C1-8 alkyl,
(b) C2-8 alkenyl,
(c) C2-8 alkynyl,
(d) halogen,
(e) nitro,
(f) nitrile,
(g) trifluoromethyl,
(h) trifluoromethoxy,
(i) $-OR^2$,
(j) $-SR^2$,
(k) $-NR^3R^4$,
(l) $-COR^5$,
(m) keto,
(n) Cyc1,
(o) C1-8 alkyl substituted by $-OR^2$, $-SR^2$, $-NR^3R^4$, $-COR^5$ or Cyc1,
(p) $-SO_2R^{10}$,
(q) –O–(C1-8 alkylene)–OR^{11},
(r) C1-8 alkyl substituted by nitrile, $-SO_2R^{10}$ or –O–(C1-8 alkylene)–OR^{11},
(s) –O–(C1-8 alkylene)–$NR^{12}R^{13}$,
(t) –S–(C1-8 alkylene)–$NR^{12}R^{13}$,
(u) C1-8 alkyl substituted by –O–(C1-8 alkylene)–$NR^{12}R^{13}$– or –S–(C1-8

alkylene)–$NR^{12}R^{13}$,

(v) C2-8 alkenyl substituted by –OR^2, –SR^2, –NR^3R^4, –COR^5, Cyc1, nitrile, –SO_2R^{10}, –O–(C1-8 alkylene)–OR^{11}, –O–(C1-8 alkylene)–$NR^{12}R^{13}$ or –S–(C1-8 alkylene)–$NR^{12}R^{13}$ or

(w) C2-8 alkynyl substituted by –OR^2, –SR^2, –NR^3R^4, –COR^5, Cyc1, nitrile, –SO_2R^{10}, –O–(C1-8 alkylene)–OR^{11}, –O–(C1-8 alkylene)–$NR^{12}R^{13}$ or –S–(C1-8 alkylene)–$NR^{12}R^{13}$,

R^2 is hydrogen, C1-8alkyl, C2-9 acyl or Cyc1,

R^3 and R^4 are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,

R^5 is hydroxy, C1-8 alkyl, C1-8 alkoxy, –NR^6R^7 or Cyc1,

R^6 and R^7 are each independently hydrogen, C1-8 alkyl or Cyc1,

R^{10} is C1-8 alkyl or Cyc1,

Cyc1 is C3-7 mono-carbocyclic ring or 5-7 membered mono-cyclic hetero ring containing 1-4 nitrogen atom(s), one oxygen atom and/or one sulfur atom,

R^{11} is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,

R^{12} and R^{13} are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,

m is 0 or an integer of 1-5;

ring A is C3-15 mono-, bi- or tri-carbocyclic ring or 5-18 membered mono-, bi- or tri-cyclic hetero ring containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s);

ring B is C5-15 mono-, bi- or tri-carbocyclic aryl or 5-18 membered mono-, bi- or tri-cyclic hetero aryl containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s);

E is a bond, –CH=CH– or –C≡C–;

R^8 is

(a) C1-8 alkyl,

(b) C1-8 alkoxy,

(c) halogen,

(d) nitro,

(e) nitrile,

(f) trifluoromethyl or

(g) trifluoromethoxy,

with the proviso that when E is a bond, then R^1 and R^8, taken together, may be optionally C1-4 alkylene;

n is 0 or an integer of 1-5;

R^9 is hydrogen, C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl;

a nontoxic salt thereof or a prodrug thereof, as an active ingredient.

2. The inhibitor of IL-6 production described in claim 1, wherein the prodrug of a compound of the formula (I) as an active ingredient is represented by a compound of the formula (IA):



(IA)

(wherein, R^{14} is C1-8 alkyl substituted with C1-8 alkyl, C1-8 alkoxy, the other symbols have the same meanings as defined in claim 1.).

3. The inhibitor of IL-6 production described in claim 1, wherein the prodrug of a compound of the formula (I) as an active ingredient is represented by comprising a compound of the formula (IB):



(IB)

(wherein, the all symbols have the same meanings as defined in claim 1.).

4. A hydroxamic acid derivative of the formula (I):



(I)

wherein, R^1 is

(a) C1-8 alkyl,

(b) C2-8 alkenyl,

(c) C2-8 alkynyl,

(d) halogen,

(e) nitro,

(f) nitrile,

(g) trifluoromethyl,

(h) trifluoromethoxy,

(i) $-OR^2$,

(j) $-SR^2$,

(k) $-NR^3R^4$,

(l) $-COR^5$,

(m) keto,

(n) Cyc1,

(o) C1-8 alkyl substituted by $-OR^2$, $-SR^2$, $-NR^3R^4$, $-COR^5$ or Cyc1,

(p) $-SO_2R^{10}$,

(q) $-O-$(C1-8 alkylene)$-OR^{11}$,

(r) C1-8 alkyl substituted by nitrile, $-SO_2R^{10}$ or $-O-$(C1-8 alkylene)$-OR^{11}$,

(s) $-O-$(C1-8 alkylene)$-NR^{12}R^{13}$,

(t) $-S-$(C1-8 alkylene)$-NR^{12}R^{13}$,

(u) C1-8 alkyl substituted by $-O-$(C1-8 alkylene)$-NR^{12}R^{13}-$ or $-S-$(C1-8 alkylene)$-NR^{12}R^{13}$,

(v) C2-8 alkenyl substituted by $-OR^2$, $-SR^2$, $-NR^3R^4$, $-COR^5$, Cyc1, nitrile, $-SO_2R^{10}$, $-O-$(C1-8 alkylene)$-OR^{11}$, $-O-$(C1-8 alkylene)$-NR^{12}R^{13}$ or $-S-$(C1-8 alkylene)$-NR^{12}R^{13}$ or

(w) C2-8 alkynyl substituted by $-OR^2$, $-SR^2$, $-NR^3R^4$, $-COR^5$, Cyc1, nitrile, –

SO_2R^{10}, –O–(C1-8 alkylene)–OR^{11}, –O–(C1-8 alkylene)–$NR^{12}R^{13}$ or –S–(C1-8 alkylene)–$NR^{12}R^{13}$,

R^2 is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,

R^3 and R^4 are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,

R^5 is hydroxyl, C1-8 alkyl, C1-8 alkoxy, $-NR^6R^7$ or Cyc1,

R^6 and R^7 are each independently hydrogen, C1-8 alkyl or Cyc1,

R^{10} is C1-8 alkyl or Cyc1,

Cyc1 is C3-7 mono-carbocyclic ring or 5-7 membered mono-cyclic hetero ring containing 1-4 nitrogen atom(s), one oxygen atom and/or one sulfur atom,

R^{11} is hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1,

R^{12} and R^{13} are each independently hydrogen, C1-8 alkyl, C2-9 acyl or Cyc1;

m is 0 or an integer of 1-5;

ring A is C3-15 mono-, bi- or tri-carbocyclic ring or 5-18 membered mono-, bi- or tri-cyclic hetero ring containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s);

ring B is C5-15 mono-, bi- or tri-carbocyclic aryl or 5-18 membered mono-, bi- or tri-cyclic hetero aryl containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s);

E is a bond, –CH=CH– or –C≡C–;

R^8 is

(a) C1-8 alkyl,

(b) C1-8 alkoxy,

(c) halogen,

(d) nitro,

(e) nitrile,

(f) trifluoromethyl or

(g) trifluoromethoxy,

with the proviso that when E is a bond then R^1 and R^8, taken together, is C1-4 alkylene optionally;

n is 0 or an integer of 1-5;

R^9 is hydrogen, C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl,

with the proviso that when E is –CH=CH– or –C≡C–, ring A is C3-7 mono-carbocyclic ring or 5-7 membered mono-cyclic hetero ring containing 1-4 nitrogen atom(s), one oxygen atom and/or one sulfur atom,
a nontoxic salt thereof or a prodrug thereof.

5. The prodrug of a compound of the formula (I) described in claim 4, which is represented by the formula (IA):



(IA)

(wherein, R^{14} is C1-8 alkyl substituted with C1-8 alkyl, C1-8 alkoxy, the other symbols have the same meaning as defined in claim 1.).

6. The prodrug of a compound of the formula (I) described in claim 4, which is represented by the formula (IB):



(IB)

(wherein, the all symbols have the same meaning as defined in claim 1.).

7. The compound described in claim 4, wherein E is a bond and ring A is C3-15 mono-, bi- or tri-carbocyclic ring.

8. The compound described in claim 4, wherein E is a bond and ring A is 5-18 membered mono-, bi- or tri-cyclic hetero ring containing 1-4 nitrogen atom(s), 1-2 oxygen atom(s) and/or 1-2 sulfur atom(s).

9. The compound described in claim 4, wherein E is –CH=CH– or –C≡C– and ring A is C3-7 mono-carbocyclic ring.

10. The compound described in claim 4, wherein E is –CH=CH– or –C≡C– and ring A is 5-7 membered mono-cyclic hetero ring containing 1-4 nitrogen atom(s), one oxygen atom and/or one sulfur atom.

11. The compound described in claim 4, which is
(1) N-hydroxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide,
(2) N-hydroxy-6-(4-biphenyl)-6-hydroxyhexanamide,
(3) N-hydroxy-6-(4-cyclohexylphenyl)-6-hydroxyhexanamide,
(4) N-hydroxy-6-(4-(4-methylphenyl)phenyl)-6-hydroxyhexanamide,
(5) N-hydroxy-6-(4-(4-methoxyphenyl)phenyl)-6-hydroxyhexanamide,
(6) N-hydroxy-6-(4-(trans-4-propylcyclohexyl)phenyl)-6-hydroxyhexanamide,
(7) (R)-N-hydroxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide,
(8) (S)-N-hydroxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide,
(9) N-hydroxy-6-(4-(benzofuran-2-yl)phenyl)-6-hydroxyhexanamide,
(10) N-hydroxy-6-(4-(pyridin-4-yl)phenyl)-6-hydroxyhexanamide,
(11) N-hydroxy-6-(4-(pyridin-3-yl)phenyl)-6-hydroxyhexanamide,
(12) N-hydroxy-6-(4-(2-chlorophenyl)phenyl)-6-hydroxyhexanamide,
(13) N-hydroxy-6-(4-(3-chlorophenyl)phenyl)-6-hydroxyhexanamide,
(14) N-hydroxy-6-(4-(4-bromophenyl)phenyl)-6-hydroxyhexanamide,
(15) N-hydroxy-6-(4-(thiophen-2-yl)phenyl)-6-hydroxyhexanamide,
(16) N-hydroxy-6-(4-(furan-2-yl)phenyl)-6-hydroxyhexanamide,
(17) N-hydroxy-6-(4-(1,3-dioxy-2,3-dihydroinden-5-yl)phenyl)-6-hydroxyhexanamide,
(18) N-hydroxy-6-(4-(4-methylthiophenyl)phenyl)-6-hydroxyhexanamide,
(19) N-hydroxy-6-(4-(naphthalen-1-yl)phenyl)-6-hydroxyhexanamide,
(20) N-hydroxy-6-(4-(naphthalen-2-yl)phenyl)-6-hydroxyhexanamide,
(21) N-hydroxy-6-(4-(4-acetylphenyl)phenyl)-6-hydroxyhexanamide,
(22) N-hydroxy-6-(4-(4-hydroxyphenyl)phenyl)-6-hydroxyhexanamide,

(23) N-hydroxy-6-(4-(dibenzofuran-4-yl)phenyl)-6-hydroxyhexanamide,
(24) N-hydroxy-6-(4-(2-methoxyphenyl)phenyl)-6-hydroxyhexanamide,
(25) N-hydroxy-6-(4-(3-methoxyphenyl)phenyl)-6-hydroxyhexanamide,
(26) N-hydroxy-6-(4-(4-trifluoromethylphenyl)phenyl)-6-hydroxyhexanamide,
(27) N-hydroxy-6-(4-(4-t-butylphenyl)phenyl)-6-hydroxyhexanamide,
(28) (R)-N-hydroxy-6-[4-(5-methylbenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,
(29) (R)-N-hydroxy-6-[4-(benzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,
(30) (R)-N-hydroxy-6-[4-(2-(4-methylthiophenyl)ethynyl)phenyl]-6-hydroxyhexanamide,
(31) (R)-N-hydroxy-6-[4-(4-methylthiophenyl)phenyl]-6-hydroxyhexanamide,
(32) (R)-N-hydroxy-6-[4-(4-(dimethylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(33) N-hydroxy-6-(4-(trans-4-butylcyclohexyl)phenyl)-6-hydroxyhexanamide,
(34) N-hydroxy-6-(4-(trans-4-hydroxycyclohexyl)phenyl)-6-hydroxyhexanamide,
(35) N-hydroxy-6-(4-cyclopentylphenyl)-6-hydroxyhexanamide,
(36) N-hydroxy-6-[4-(morpholin-4-yl)phenyl]-6-hydroxyhexanamide,
(37) N-hydroxy-6-[3-(4-chlorophenyl)phenyl]-6-hydroxyhexanamide,
(38) N-hydroxy-6-[2-(4-chlorophenyl)phenyl]-6-hydroxyhexanamide,
(39) N-hydroxy-6-[4-((1E)-2-phenylvinyl)phenyl]-6-hydroxyhexanamide,
(40) N-hydroxy-6-[4-((1E)-2-(pyridin-4-yl)vinyl)phenyl]-6-hydroxyhexanamide,
(41) N-hydroxy-6-[4-((1E)-2-(pyridin-2-yl)vinyl)phenyl]-6-hydroxyhexanamide,
(42) N-hydroxy-6-[4-(4-chlorophenyl)phenyl]-6-hydroxyheptanamide,
(43) N-hydroxy-6-[4-(4-chlorophenyl)phenyl]-6-hydroxy-7-octenamide,
(44) N-hydroxy-6-(4-biphenyl)-6-hydroxyheptanamide,
(45) (+)-N-hydroxy-6-[4-(4-ethylphenyl)phenyl]-6-hydroxyheptanamide,
(46) (-)-N-hydroxy-6-[4-(4-ethylphenyl)phenyl]-6-hydroxyheptanamide,
(47) (R)-N-hydroxy-6-(4-biphenyl)-6-hydroxyhexanamide,
(48) (R)-N-hydroxy-6-[4-(4-methylphenyl)phenyl]-6-hydroxyhexanamide,
(49) (R)-N-hydroxy-6-[4-(3-methylphenyl)phenyl]-6-hydroxyhexanamide,
(50) (R)-N-hydroxy-6-[4-(benzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,
(51) (R)-N-hydroxy-6-[4-(2-phenylethynyl)phenyl]-6-hydroxyhexanamide,

(52) (R)-N-hydroxy-6-[4-(benzothiophen-2-yl)phenyl]-6-hydroxyhexanamide,
(53) (R)-N-hydroxy-6-[4-(4-(cyanomethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(54) (R)-N-hydroxy-6-[4-(4-ethylphenyl)phenyl]-6-hydroxyhexanamide,
(55) (R)-N-hydroxy-6-[4-(4-propylphenyl)phenyl]-6-hydroxyhexanamide,
(56) (R)-N-hydroxy-6-[4-(4-biphenyl)phenyl]-6-hydroxyhexanamide,
(57) (R)-N-hydroxy-6-[4-(1-methylpiperidin-4-yl)phenyl]-6-hydroxyhexanamide,
(58) (R)-N-hydroxy-6-[4-(indol-2-yl)phenyl]-6-hydroxyhexanamide,
(59) (R)-N-hydroxy-6-[4-(4-cyanophenyl)phenyl]-6-hydroxyhexanamide,
(60) (R)-N-hydroxy-6-[4-phenyl-2-methylphenyl]-6-hydroxyhexanamide,
(61) (R)-N-hydroxy-6-(4-cycloheptylphenyl)-6-hydroxyhexanamide,
(62) (R)-N-hydroxy-6-(9,10-dihydrophenanthren-2-yl)-6-hydroxyhexanamide,
(63) (R)-N-hydroxy-6-[4-(1-ethoxycarbonylpiperidin-4-yl)phenyl]-6-hydroxyhexanamide,
(64) (R)-N-hydroxy-6-[4-(4-(N-methylcarbamoyl)phenyl)phenyl]-6-hydroxyhexanamide,
(65) (R)-N-hydroxy-6-(4-cyclohexylphenyl)-6-hydroxyhexanamide,
(66) (R)-N-hydroxy-6-[4-(5-hydroxybenzofuran-2-yl)phenyl]-6-hydroxyhexanamide,
(67) (R)-N-hydroxy-6-[4-(2-(4-methylphenyl)ethynyl)phenyl]-6-hydroxyhexanamide,
(68) (R)-N-hydroxy-6-[4-((1E)-2-(4-methylphenyl)vinyl)phenyl]-6-hydroxyhexanamide,
(69) (R)-N-hydroxy-6-[4-(4-trifluoromethoxyphenyl)phenyl]-6-hydroxyhexanamide,
(70) (R)-N-hydroxy-6-[4-(4-ethylthiophenyl)phenyl]-6-hydroxyhexanamide,
(71) (R)-N-hydroxy-6-[4-(4-methoxyphenyl)phenyl]-6-hydroxyhexanamide,
(72) (R)-N-hydroxy-6-[4-(4-(1-methylethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(73) (R)-N-hydroxy-6-[4-(4-(N,N-dimethylcarbamoylmethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(74) (R)-N-hydroxy-6-[4-(benzothiazol-2-yl)phenyl]-6-hydroxyhexanamide,
(75) (R)-N-hydroxy-6-[4-(4-(methoxymethoxymethyl)phenyl)phenyl]-6-

hydroxyhexanamide,

(76) (R)-N-hydroxy-6-[4-(6-methoxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,

(77) (R)-N-hydroxy-6-[4-(6-methylbenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,

(78) (R)-N-hydroxy-6-[4-(4-methoxymethylphenyl)phenyl]-6-hydroxyhexanamide,

(79) (R)-N-hydroxy-6-[4-(5-methoxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,

(80) (R)-N-hydroxy-6-[4-(4-methoxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,

(81) (R)-N-hydroxy-6-[4-(4-(piperidin-1-ylmethyl)phenyl)phenyl]-6-hydroxyhexanamide,

(82) (R)-N-hydroxy-6-[4-(4-hydroxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,

(83) (R)-N-hydroxy-6-[4-(6-hydroxybenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,

(84) (R)-N-hydroxy-6-[4-((1E)-2-(4-methylthiophenyl)vinyl)phenyl]-6-hydroxyhexanamide,

(85) (R)-N-hydroxy-6-[4-(5-methoxybenzofuran-2-yl)phenyl]-6-hydroxyhexanamide,

(86) (R)-N-hydroxy-6-[4-(5-methylthiobenzofuran-2-yl)phenyl]-6-hydroxyhexanamide,

(87) (R)-N-hydroxy-6-[4-(4-(2-(dimethylamino)ethyl)phenyl)phenyl]-6-hydroxyhexanamide,

(88) (R)-N-hydroxy-6-[4-(4-(2-(dimethylamino)ethoxy)phenyl)phenyl]-6-hydroxyhexanamide,

(89) (R)-N-hydroxy-6-[4-(4-(2-(diethylamino)ethyl)phenyl)phenyl]-6-hydroxyhexanamide,

(90) (R)-N-hydroxy-6-[4-(4-(2-hydroxyethyl)phenyl)phenyl]-6-hydroxyhexanamide,

(91) (S)-N-hydroxy-6-[4-(4-methylthiophenyl)phenyl]-6-hydroxyhexanamide,

(92) (S)-N-hydroxy-6-[4-(2-(4-methylthiophenyl)ethynyl)phenyl]-6-hydroxyhexanamide,
(93) (S)-N-hydroxy-6-[4-(benzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,
(94) (S)-N-hydroxy-6-[4-(5-methylbenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,
(95) (S)-N-hydroxy-6-[4-(4-(dimethylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(96) (R)-N-hydroxy-6-[4-(4-(morpholin-4-ylmethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(97) (R)-N-hydroxy-6-[4-(4-(dipropylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(98) (R)-N-hydroxy-6-(5-phenylthiophen-2-yl)-6-hydroxyhexanamide,
(99) (R)-N-hydroxy-6-(5-phenylbenzofuran-2-yl)-6-hydroxyhexanamide,
(100) (R)-N-hydroxy-6-[4-(4-(methoxycarbonyl)phenyl)phenyl]-6-hydroxyhexanamide,
(101) (R)-N-hydroxy-6-[4-(4-carboxyphenyl)phenyl]-6-hydroxyhexanamide,
(102) (R)-N-hydroxy-6-[4-(4-methylsulfonylphenyl)phenyl]-6-hydroxyhexanamide,
(103) (R)-N-hydroxy-6-[4-(4-hydroxymethylphenyl)phenyl]-6-hydroxyhexanamide,
(104) (R)-N-hydroxy-6-[4-(4-(2-(morpholin-4-yl)ethoxy)phenyl)phenyl]-6-hydroxyhexanamide,
(105) (R)-N-hydroxy-6-[4-(4-(2-(morpholin-4-yl)ethyl)phenyl)phenyl]-6-hydroxyhexanamide
or a nontoxic salt thereof.

12. The compound described in claim 5, which is:
(1) N-(1-methoxy-1-methyl)ethoxy-6-(4-(4-chlorophenyl)phenyl)-6-hydroxyhexanamide,
(2) N-(1-methoxy-1-methyl)ethoxy-6-(4-(benzofuran-2-yl)phenyl)-6-hydroxyhexanamide,
(3) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(5-methylbenzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,

(4) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(benzoxazol-2-yl)phenyl]-6-hydroxyhexanamide,
(5) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(2-(4-methylthiophenyl)ethynyl)phenyl]-6-hydroxyhexanamide,
(6) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-methylthiophenyl)phenyl]-6-hydroxyhexanamide,
(7) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(dimethylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(8) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(morpholin-4-ylmethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(9) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(dipropylaminomethyl)phenyl)phenyl]-6-hydroxyhexanamide,
(10) N-methoxy-6-[4-(4-chlorophenyl)phenyl]-6-hydroxyhexanamide,
(11) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(2-(morpholin-4-yl)ethoxy)phenyl)phenyl]-6-hydroxyhexanamide,
(12) (R)-N-(1-methoxy-1-methyl)ethoxy-6-[4-(4-(2-(morpholin-4-yl)ethyl)phenyl)phenyl]-6-hydroxyhexanamide,
or a nontoxic salt thereof.

13. The compound described in claim 6, which is
(1) (R)-5-(5,5-dimethyl-1,4,2-dioxazolin-3-yl)-1-[4-(5-methylbenzoxazol-2-yl)phenyl]pentan-1-ol,
(2) (R)-5-(5,5-dimethyl-1,4,2-dioxazolin-3-yl)-1-[4-(4-methylthiophenyl)phenyl]pentan-1-ol,
(3) (R)-5-(5,5-dimethyl-1,4,2-dioxazolin-3-yl)-1-[4-(4-(dimethylaminomethyl)phenyl)phenyl]pentan-1-ol,
or a nontoxic salt thereof.